Publications by authors named "L Vacca"
Minimally invasive surgery could improve cosmetic outcomes and reduce the risks of surgical injury with less postoperative pain and a quicker patient's discharge. Recently, transvaginal natural orifice transluminal endoscopic surgery (vNOTES) has been introduced in urogynecology with exciting results. After PROSPERO registration (n°CRD42023406815), we performed a comprehensive literature search on Pubmed, Embase, and Cochrane CENTRAL, including peer-reviewed studies evaluating transvaginal natural orifice transluminal endoscopic surgery.
View Article and Find Full Text PDFRecurrent pelvic prolapse after pelvic organ prolapse suspension (POPS): Analysis and treatment of an emerging clinical issue.
Eur J Obstet Gynecol Reprod Biol
November 2024
Article Synopsis
- The study investigates the outcomes of a new surgical technique called pelvic organ prolapse suspension (POPS) for treating pelvic organ prolapse (POP) and rectal prolapse, focusing on patients who experience recurrence of symptoms after the procedure.
- The research involved 25 women, primarily menopausal, who mostly had recurrent posterior vaginal wall prolapse and associated obstructed defecation syndrome, with all undergoing laparoscopic ventral rectopexy surgery.
- Findings indicated no anatomical recurrences after surgery and a significant improvement in patient symptoms, suggesting that a multidisciplinary approach and the use of minimally invasive techniques can be effective for managing recurrent POP.
Article Synopsis
- Current estimates of genetic variants linked to Parkinson's disease (PD) show limitations and biases across different populations, complicating patient recruitment for clinical trials focused on genetic therapies.
- The Rostock Parkinson's disease (ROPAD) study analyzes data from 12,580 PD patients across 16 countries, revealing that 14.8% had a genetic test positive for PD-related variants, particularly in specific genes like GBA1 and LRRK2.
- Findings indicate higher positivity rates in patients with earlier onset (age ≤ 50) or a positive family history, emphasizing the need for more extensive genetic investigation to improve patient stratification for future clinical trials.